KRAS and lung adenocarcinoma: Our observations on FTi sensitivity led us to combine tipifarnib, a clinically approved potent farnesyl-transferase inhibitor with sotorasib, a novel KRAS-G12C inhibitor in lung adenocarcinoma cell lines.